Related Experiment Video
Updated: May 12, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Summary
This review explores cardiorenal syndromes (CRS), focusing on heart failure pathogenesis and therapeutic targets. It discusses biomarkers, treatment challenges, and novel technologies for managing this complex condition.
Area of Science:
- Cardiorenal medicine
- Cardiology
- Nephrology
Background:
- Cardiorenal syndromes (CRS) represent a complex interplay between cardiac and renal dysfunction.
- Understanding the pathogenesis of heart failure is crucial for addressing CRS.
- Current therapeutic strategies face significant challenges in reversing the pathogenetic continuum of CRS.
Discussion:
- This review examines the classification and underlying mechanisms of cardiorenal syndromes.
- It highlights the search for effective therapeutic targets and reliable biomarkers for both heart and kidney failure.
- Difficulties in managing CRS and reverting its progression are critically analyzed.
Key Insights:
- Accurate classification of CRS is essential for targeted treatment.
- Identifying specific biomarkers can aid in early diagnosis and prognosis of CRS.
- Novel therapeutic approaches are needed to overcome current treatment limitations.
Outlook:
- Future research should focus on innovative technologies for CRS treatment.
- Developing targeted therapies based on a deeper understanding of CRS pathogenesis is promising.
- Improving patient outcomes requires a multidisciplinary approach to managing cardiorenal conditions.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:27Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.